Cargando…

The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy

BACKGROUND: Studies evaluating new systemic agents tend to report severe toxicities only, while the cumulative effect of multiple lower grade adverse events (AEs) may have an additional negative impact on patient quality of life (QOL). In the current observational cohort study, we evaluated whether,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuurhuizen, Claudia SEW, Verheul, Henk MW, Braamse, Annemarie MJ, Buffart, Laurien M, Bloemendal, Haiko J, Dekker, Joost, Konings, Inge RHM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124444/
https://www.ncbi.nlm.nih.gov/pubmed/30214296
http://dx.doi.org/10.2147/CMAR.S166468
_version_ 1783353027941367808
author Schuurhuizen, Claudia SEW
Verheul, Henk MW
Braamse, Annemarie MJ
Buffart, Laurien M
Bloemendal, Haiko J
Dekker, Joost
Konings, Inge RHM
author_facet Schuurhuizen, Claudia SEW
Verheul, Henk MW
Braamse, Annemarie MJ
Buffart, Laurien M
Bloemendal, Haiko J
Dekker, Joost
Konings, Inge RHM
author_sort Schuurhuizen, Claudia SEW
collection PubMed
description BACKGROUND: Studies evaluating new systemic agents tend to report severe toxicities only, while the cumulative effect of multiple lower grade adverse events (AEs) may have an additional negative impact on patient quality of life (QOL). In the current observational cohort study, we evaluated whether, in patients with metastatic colorectal cancer receiving first-line chemotherapy, cumulative toxicity comprising all grades of AEs is more predictive for QOL than cumulative toxicity due to only high-grade AEs. METHODS: One hundred and five patients starting treatment completed the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) questionnaire at baseline and 10 weeks. AEs, clinical outcomes, and demographics were retrieved from patient records. Cumulative toxicity scores were calculated in three ways: total number of high-grade AEs, total number of all-grade AEs, and total number of AEs multiplied by their grade (the severity score). Relations between cumulative toxicity scores and QOL were studied using multivariable linear regression analyses. RESULTS: The mean age of patients was 65 years, 68% were male, and 84% received oxaliplatin-based chemotherapy. A higher total number of AEs of all grades (B=−2.4, 95% CI=–3.9; −0.9) and the severity score (B=–1.4, 95% CI=–2.3; −0.5) were predictive for clinically relevant changes in physical QOL, whereas the total high-grade AEs was not. None of the cumulative toxicity scores were predictive for global QOL. CONCLUSION: Cumulative toxicity scores comprising all grades of AEs provide a better measure of treatment burden than a toxicity score comprising high-grade AEs only. Physical QOL seems to be more affected by AEs than global QOL. Our results emphasize that future clinical trials should present cumulative toxicity scores comprising all AE grades as well as physical QOL instead of global QOL.
format Online
Article
Text
id pubmed-6124444
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61244442018-09-13 The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy Schuurhuizen, Claudia SEW Verheul, Henk MW Braamse, Annemarie MJ Buffart, Laurien M Bloemendal, Haiko J Dekker, Joost Konings, Inge RHM Cancer Manag Res Original Research BACKGROUND: Studies evaluating new systemic agents tend to report severe toxicities only, while the cumulative effect of multiple lower grade adverse events (AEs) may have an additional negative impact on patient quality of life (QOL). In the current observational cohort study, we evaluated whether, in patients with metastatic colorectal cancer receiving first-line chemotherapy, cumulative toxicity comprising all grades of AEs is more predictive for QOL than cumulative toxicity due to only high-grade AEs. METHODS: One hundred and five patients starting treatment completed the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) questionnaire at baseline and 10 weeks. AEs, clinical outcomes, and demographics were retrieved from patient records. Cumulative toxicity scores were calculated in three ways: total number of high-grade AEs, total number of all-grade AEs, and total number of AEs multiplied by their grade (the severity score). Relations between cumulative toxicity scores and QOL were studied using multivariable linear regression analyses. RESULTS: The mean age of patients was 65 years, 68% were male, and 84% received oxaliplatin-based chemotherapy. A higher total number of AEs of all grades (B=−2.4, 95% CI=–3.9; −0.9) and the severity score (B=–1.4, 95% CI=–2.3; −0.5) were predictive for clinically relevant changes in physical QOL, whereas the total high-grade AEs was not. None of the cumulative toxicity scores were predictive for global QOL. CONCLUSION: Cumulative toxicity scores comprising all grades of AEs provide a better measure of treatment burden than a toxicity score comprising high-grade AEs only. Physical QOL seems to be more affected by AEs than global QOL. Our results emphasize that future clinical trials should present cumulative toxicity scores comprising all AE grades as well as physical QOL instead of global QOL. Dove Medical Press 2018-08-29 /pmc/articles/PMC6124444/ /pubmed/30214296 http://dx.doi.org/10.2147/CMAR.S166468 Text en © 2018 Schuurhuizen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Schuurhuizen, Claudia SEW
Verheul, Henk MW
Braamse, Annemarie MJ
Buffart, Laurien M
Bloemendal, Haiko J
Dekker, Joost
Konings, Inge RHM
The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
title The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
title_full The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
title_fullStr The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
title_full_unstemmed The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
title_short The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
title_sort predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124444/
https://www.ncbi.nlm.nih.gov/pubmed/30214296
http://dx.doi.org/10.2147/CMAR.S166468
work_keys_str_mv AT schuurhuizenclaudiasew thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT verheulhenkmw thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT braamseannemariemj thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT buffartlaurienm thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT bloemendalhaikoj thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT dekkerjoost thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT koningsingerhm thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT schuurhuizenclaudiasew predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT verheulhenkmw predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT braamseannemariemj predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT buffartlaurienm predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT bloemendalhaikoj predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT dekkerjoost predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy
AT koningsingerhm predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy